<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338569</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000625</org_study_id>
    <nct_id>NCT03338569</nct_id>
  </id_info>
  <brief_title>Vitamin C and Septic Shock</brief_title>
  <official_title>Evaluating Vitamin C in Septic Shock: A Randomized Double Blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled clinical trial to compare Vitamin C&#xD;
      versus placebo for patients presenting to the ICU with a diagnosis of septic shock.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-site, randomized, double-blind, placebo-controlled trial comparing a regimen&#xD;
      of moderate-dose (6000 mg per day) Vitamin C supplementation versus placebo for the treatment&#xD;
      of patients presenting to the ICU with septic shock. Both groups will continue to receive all&#xD;
      other standard of care measures for septic shock as clinically indicated. Groups will be&#xD;
      enrolled and receive study drug/placebo for 4 days (96 hours) or until 24 hours post-last&#xD;
      pressor dose, whichever is sooner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Actual">August 10, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With ICU Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Outcome is reported as the number of patients who expired while receiving care in the intensive care unit (ICU).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All Cause Mortality at 28 Days</measure>
    <time_frame>28 days</time_frame>
    <description>Outcome is reported as the number of participants who have expired at 28 days post intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Vasopressor Therapy</measure>
    <time_frame>28 days</time_frame>
    <description>Outcome is reported as the duration in hours of vasopressor therapy post intervention administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU Stay Post Intervention Administration</measure>
    <time_frame>28 days</time_frame>
    <description>Outcome is reported as the duration (in days) that participants require care in the intensive care unit (ICU) post intervention administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Lactate Clearance Post Intervention Administration</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Lactate Clearance Post Intervention Administration</measure>
    <time_frame>24, 48, 72, and 96 hours post intervention</time_frame>
    <description>Outcome is reported as the number of participants who clear lactate from the bloodstream at 24, 48, 72, and 96 hours post intervention. Clearance is defined as a serum concentration of 2.0 mmol/l or less.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Procalcitonin Clearance Post Intervention Administration</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Need for Renal Replacement Therapy</measure>
    <time_frame>4 days</time_frame>
    <description>Outcome is reported as the number of participants who require renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine</measure>
    <time_frame>Baseline and 4 days</time_frame>
    <description>Outcome is report as the change in serum creatinine between baseline and 4 days following treatment. Outcome is reported in units of mg/dl.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sequential Organ Failure Assessment (SOFA) Score</measure>
    <time_frame>Baseline and 4 days</time_frame>
    <description>SOFA score is a mortality prediction score that is based on the degree of dysfunction of 6 organ systems. Total scores range from 0 to 24, with higher scores indicating higher likely mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Acute Physiology and Chronic Health Evaluation (APACHE) Scores</measure>
    <time_frame>Baseline and 4 days</time_frame>
    <description>APACHE score is a severity-of-disease classification system that is calculated from a patient's age and 12 routine physiological measurements. Total scores are computed based on several measurements and range from 0 to 71 with higher scores corresponding to more severe disease and a higher risk of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Intravenous Fluid Administered</measure>
    <time_frame>24 hours</time_frame>
    <description>Outcome is reported as the total volume of intravenous fluid (in liters) administered to participants during 24 hours following the initiation of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Septic Shock</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Placebo designed to mimic intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6000 mg per day Vitamin C supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Continuous infusion of vitamin C</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>ascorbic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo designed to mimic intervention</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Capability to provide written consent from participant or legally authorized&#xD;
             representative (LAR) if the participant is unable or incapacitated due to severity of&#xD;
             illness.&#xD;
&#xD;
               -  Age ≥ 18 years&#xD;
&#xD;
               -  Septic shock as pragmatically defined as:&#xD;
&#xD;
                  o Order for intravenous antimicrobials with either procalcitonin &gt; 2 mg/dL within&#xD;
                  24 hours of enrollment OR other clinical suspicion of infection or confirmed&#xD;
                  infection AND&#xD;
&#xD;
               -  Hypotension requiring vasopressor therapy, despite fluid resuscitation of at&#xD;
                  least 30 cc/kg AND&#xD;
&#xD;
               -  Lactate &gt; 2 mmol/L 24 hr prior to enrollment AND&#xD;
&#xD;
               -  Presence of sepsis defined as equal to or greater than 2 SIRS criteria and/or&#xD;
                  acute increase in qSOFA score of 2 points or more.&#xD;
&#xD;
                    -  SIRS criteria: 1) Temperature greater than 38° or less than 36° Celsius. 2)&#xD;
                       Heart rate greater than 90 beats per minute. 3) Respiratory rate greater&#xD;
                       than 20 breaths per minute OR arterial carbon dioxide tension less than 32&#xD;
                       mmHg. 4) White blood cell count greater than 12,000 cell/µL, less than 4,000&#xD;
                       cells/µL, OR band cells greater than 10% of the total white blood cell&#xD;
                       population.&#xD;
&#xD;
                    -  qSOFA: 1 point each is assigned for: 1) systolic blood pressure below 100,&#xD;
                       2) respiratory rate greater than 22, and 3) mental status not at baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Unable to start infusion within 24 hours of septic shock identification&#xD;
&#xD;
               -  Currently pregnant or breastfeeding&#xD;
&#xD;
               -  Patient to receive comfort measures only&#xD;
&#xD;
               -  Cardiac Arrest&#xD;
&#xD;
               -  Cardiovascular Surgery patients receiving prophylactic peri-operative antibiotics&#xD;
                  &lt; 48 hours post-operation&#xD;
&#xD;
               -  Participation in another study involving an investigational product within 30&#xD;
                  days of the baseline visit&#xD;
&#xD;
               -  Allergy to Vitamin C&#xD;
&#xD;
               -  History of nephrolithiasis&#xD;
&#xD;
               -  History of G6PD deficiency&#xD;
&#xD;
               -  ESRD patients, transplant eligible on dialysis currently taking vitamin C&#xD;
                  supplementation&#xD;
&#xD;
               -  Clinical course that treating clinician decides would preclude safe participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <results_first_submitted>June 14, 2021</results_first_submitted>
  <results_first_submitted_qc>July 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2021</results_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03338569/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03338569/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
        </group>
        <group group_id="P2">
          <title>Intervention</title>
          <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
        </group>
        <group group_id="B2">
          <title>Intervention</title>
          <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" lower_limit="60.7" upper_limit="80"/>
                    <measurement group_id="B2" value="68.9" lower_limit="60.1" upper_limit="79.9"/>
                    <measurement group_id="B3" value="71" lower_limit="60.1" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With ICU Mortality</title>
        <description>Outcome is reported as the number of patients who expired while receiving care in the intensive care unit (ICU).</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ICU Mortality</title>
          <description>Outcome is reported as the number of patients who expired while receiving care in the intensive care unit (ICU).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>All Cause Mortality at 28 Days</title>
        <description>Outcome is reported as the number of participants who have expired at 28 days post intervention</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality at 28 Days</title>
          <description>Outcome is reported as the number of participants who have expired at 28 days post intervention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Vasopressor Therapy</title>
        <description>Outcome is reported as the duration in hours of vasopressor therapy post intervention administration</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Vasopressor Therapy</title>
          <description>Outcome is reported as the duration in hours of vasopressor therapy post intervention administration</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="16.4" upper_limit="45.2"/>
                    <measurement group_id="O2" value="27.7" lower_limit="13.6" upper_limit="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of ICU Stay Post Intervention Administration</title>
        <description>Outcome is reported as the duration (in days) that participants require care in the intensive care unit (ICU) post intervention administration</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of ICU Stay Post Intervention Administration</title>
          <description>Outcome is reported as the duration (in days) that participants require care in the intensive care unit (ICU) post intervention administration</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.5" upper_limit="5.3"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.8" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Lactate Clearance Post Intervention Administration</title>
        <time_frame>28 days</time_frame>
        <population>Measure was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Lactate Clearance Post Intervention Administration</title>
          <population>Measure was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Lactate Clearance Post Intervention Administration</title>
        <description>Outcome is reported as the number of participants who clear lactate from the bloodstream at 24, 48, 72, and 96 hours post intervention. Clearance is defined as a serum concentration of 2.0 mmol/l or less.</description>
        <time_frame>24, 48, 72, and 96 hours post intervention</time_frame>
        <population>All participants who completed 96 hours of testing are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Lactate Clearance Post Intervention Administration</title>
          <description>Outcome is reported as the number of participants who clear lactate from the bloodstream at 24, 48, 72, and 96 hours post intervention. Clearance is defined as a serum concentration of 2.0 mmol/l or less.</description>
          <population>All participants who completed 96 hours of testing are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Procalcitonin Clearance Post Intervention Administration</title>
        <time_frame>4 days</time_frame>
        <population>Outcome was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Procalcitonin Clearance Post Intervention Administration</title>
          <population>Outcome was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Need for Renal Replacement Therapy</title>
        <description>Outcome is reported as the number of participants who require renal replacement therapy</description>
        <time_frame>4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Need for Renal Replacement Therapy</title>
          <description>Outcome is reported as the number of participants who require renal replacement therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine</title>
        <description>Outcome is report as the change in serum creatinine between baseline and 4 days following treatment. Outcome is reported in units of mg/dl.</description>
        <time_frame>Baseline and 4 days</time_frame>
        <population>All participants for whom baseline and 96-hour creatinine data is available are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine</title>
          <description>Outcome is report as the change in serum creatinine between baseline and 4 days following treatment. Outcome is reported in units of mg/dl.</description>
          <population>All participants for whom baseline and 96-hour creatinine data is available are included in this analysis.</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-0.1" upper_limit="0.7"/>
                    <measurement group_id="O2" value=".4" lower_limit="0" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sequential Organ Failure Assessment (SOFA) Score</title>
        <description>SOFA score is a mortality prediction score that is based on the degree of dysfunction of 6 organ systems. Total scores range from 0 to 24, with higher scores indicating higher likely mortality.</description>
        <time_frame>Baseline and 4 days</time_frame>
        <population>All participants for whom baseline and 96-hour SOFA scores were available are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sequential Organ Failure Assessment (SOFA) Score</title>
          <description>SOFA score is a mortality prediction score that is based on the degree of dysfunction of 6 organ systems. Total scores range from 0 to 24, with higher scores indicating higher likely mortality.</description>
          <population>All participants for whom baseline and 96-hour SOFA scores were available are included in this analysis.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Acute Physiology and Chronic Health Evaluation (APACHE) Scores</title>
        <description>APACHE score is a severity-of-disease classification system that is calculated from a patient's age and 12 routine physiological measurements. Total scores are computed based on several measurements and range from 0 to 71 with higher scores corresponding to more severe disease and a higher risk of death.</description>
        <time_frame>Baseline and 4 days</time_frame>
        <population>All participants for whom APACHE scores at baseline and 4 days post intervention were available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Acute Physiology and Chronic Health Evaluation (APACHE) Scores</title>
          <description>APACHE score is a severity-of-disease classification system that is calculated from a patient's age and 12 routine physiological measurements. Total scores are computed based on several measurements and range from 0 to 71 with higher scores corresponding to more severe disease and a higher risk of death.</description>
          <population>All participants for whom APACHE scores at baseline and 4 days post intervention were available are included.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Intravenous Fluid Administered</title>
        <description>Outcome is reported as the total volume of intravenous fluid (in liters) administered to participants during 24 hours following the initiation of study treatment.</description>
        <time_frame>24 hours</time_frame>
        <population>All participants for whom total intravenous fluid administration data was available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Total Intravenous Fluid Administered</title>
          <description>Outcome is reported as the total volume of intravenous fluid (in liters) administered to participants during 24 hours following the initiation of study treatment.</description>
          <population>All participants for whom total intravenous fluid administration data was available are included.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 hours post initiation of study treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".76" lower_limit=".36" upper_limit="1.26"/>
                    <measurement group_id="O2" value="1.07" lower_limit=".72" upper_limit="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post initiation of study treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" lower_limit="1.98" upper_limit="4.7"/>
                    <measurement group_id="O2" value="3.59" lower_limit="2.52" upper_limit="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo designed to mimic intervention&#xD;
Placebo: Placebo designed to mimic intervention</description>
        </group>
        <group group_id="E2">
          <title>Intervention</title>
          <description>Vitamin C&#xD;
Vitamin C: Continuous infusion of vitamin C</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Troponin w/o ST elevation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>New or worsening heart failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Arrythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Bleeding event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>New or worsening heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Arrythmia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Elevated Troponin w/o ST elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Maculopapular rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald Reilkoff, MD</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-624-0999</phone>
      <email>rreilkof@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

